Pharmacogenomics: what is next?
Pharmacogenomics is moving from a candidate gene strategy to large scale approaches. This is in line with the new paradigm of linking a trait to (a) pathway(s) rather than to single genes. In addition, breakthroughs in genomics offer a non-a priori assessment of implicated genes, expanding the possi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00086/full |
| _version_ | 1818515393985118208 |
|---|---|
| author | Julia edi Iulio Margalida eRotger |
| author_facet | Julia edi Iulio Margalida eRotger |
| author_sort | Julia edi Iulio |
| collection | DOAJ |
| description | Pharmacogenomics is moving from a candidate gene strategy to large scale approaches. This is in line with the new paradigm of linking a trait to (a) pathway(s) rather than to single genes. In addition, breakthroughs in genomics offer a non-a priori assessment of implicated genes, expanding the possibilities in pharmacogenomics research. In this review, we discuss the pros and cons of new concepts in study design and on high throughput approaches to be implemented in the near future. |
| first_indexed | 2024-12-11T00:28:19Z |
| format | Article |
| id | doaj.art-e7ef721be02745eba4cb639cd19196d5 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-11T00:28:19Z |
| publishDate | 2012-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e7ef721be02745eba4cb639cd19196d52022-12-22T01:27:28ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122012-01-01210.3389/fphar.2011.0008619140Pharmacogenomics: what is next?Julia edi Iulio0Margalida eRotger1Institute of Microbiology, University Hospital Center, University of LausanneInstitute of Microbiology, University Hospital Center, University of LausannePharmacogenomics is moving from a candidate gene strategy to large scale approaches. This is in line with the new paradigm of linking a trait to (a) pathway(s) rather than to single genes. In addition, breakthroughs in genomics offer a non-a priori assessment of implicated genes, expanding the possibilities in pharmacogenomics research. In this review, we discuss the pros and cons of new concepts in study design and on high throughput approaches to be implemented in the near future.http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00086/fullGWASpharmacogenomicsnext generation sequencing |
| spellingShingle | Julia edi Iulio Margalida eRotger Pharmacogenomics: what is next? Frontiers in Pharmacology GWAS pharmacogenomics next generation sequencing |
| title | Pharmacogenomics: what is next? |
| title_full | Pharmacogenomics: what is next? |
| title_fullStr | Pharmacogenomics: what is next? |
| title_full_unstemmed | Pharmacogenomics: what is next? |
| title_short | Pharmacogenomics: what is next? |
| title_sort | pharmacogenomics what is next |
| topic | GWAS pharmacogenomics next generation sequencing |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2011.00086/full |
| work_keys_str_mv | AT juliaediiulio pharmacogenomicswhatisnext AT margalidaerotger pharmacogenomicswhatisnext |